

- Home
- News
- Technology
- Opinion
- Directory
- Subscribe
- Webinars

[Home](#) / [News](#) / [One step up: achieving compliance for excipient GMPs](#)


One step up: achieving compliance for excipient GMPs

by [Kaat Bracquiné](#)

[2](#) [RSS](#) [Print](#)

Kaat Bracquiné, quality and regulatory affairs, Capsugel explains how to achieve compliance with the new EU guidelines for excipient GMPs





Last year, the European Union published new guidelines (2015/C 95/02) that require the pharmaceutical industry to demonstrate appropriate excipient Good Manufacturing Practices (GMPs) through a formalised risk assessment. As of the implementation deadline in March 2016, pharmaceutical companies should have conducted these formalised risk assessments and have them available to EU regulatory inspectors.

Excipient GMPs provide assurance that excipients are consistently produced and controlled to the quality standards appropriate to their intended use and as required by product specification. The EU guidelines require all manufacturing authorization holders to:

- Determine the risk profile of each excipient, taking into account the excipient source (animal, mineral, synthetic, etc.) and its use and function in the medical product;
- Determine the appropriate GMP, associated with the risk of the excipient;
- Perform a gap analysis of the activities and capabilities of each



GDMO invests €40m in better serialisation

Given these obstacles, some pharmaceutical companies may not yet be prepared for the new EU guidelines. Now that the deadline has passed, companies that have not completed their formalised risk assessments face the potential of EU regulatory warnings and other actions. With that in mind, what steps can these companies take to more quickly achieve compliance with the EU guidelines?

EDM, QIP and other companies with reference recommendations from their industry peers. For example, the EMA Visional Pharmaceutical Excipients Council Europe (IPEC Europe), the industrial association for producers, distributors and users of pharmaceutical excipients, recently published a comprehensive 'how-to' document to help pharmaceutical companies comply with

the new EU guidelines. The document, released in March, includes practical and technical information on how to implement the steps necessary to achieve compliance. Additionally, it contains several useful annexes, with a.o. legislative tools for risk assessment, available GMP/quality standards facilitating gap analysis with the current EU requirements. Hermes Pharma, an expert in user-friendly solid oral dosage forms, has announced the commercial implementation of hot melt coating (HMC) in its production facility. [more »](#)

Companies can seek out specialised excipient manufacturers – some of which, like Capsugel, participated on IPEC Europe's risk-assessment task force to develop the



Software suite joins the dots in clinical trials

A new software suite for clinical trials has been launched to digitally connect sponsors, sites, medical devices and pharmaceutical customers to significantly reduce their efforts needed

1. **Independent GMP Certification:** Specialized excipient manufacturers with EXCiPACT-certified facilities can help

to prove compliance with the new EU guidelines. EXCiPACT



certification provides credible, independent validation that the excipient manufacturer maintains excipient GMPs and complies with current EU regulations. This certification may replace the on-site

audit of excipient manufacturers by pharmaceutical companies,

saving timing and resources. In 2014, Capsugel became the first hard

copy of the manufacturer to receive independent EXCiPACT certification

for excipient GMPs at our facilities in Bornem, Belgium and Colmar, France. To date, Capsugel remains the only capsule manufacturer to

receive this certification.

1. **Useful Regulatory Compliance Support Packages:**

Specialised excipient manufacturers that offer compliance support packages for their products can help pharmaceutical companies with compliance efforts. These packages assist customers in completing their risk assessment by providing current technical information on the starting materials of their products to help facilitate required risk-scoring. They can replace the resource-intensive process of collecting excipient product information linked to source and origin, which is required by the EU guidelines.

1. **Ongoing Regulatory Expertise:** Specialised excipient manufacturers that are involved and active in IPEC Europe, and thoroughly adhere to IPEC standards, offer pharmaceutical customers with useful experience and understanding of the changing excipient requirements in Europe. These manufacturers can advise companies on ways to achieve and maintain compliance in today's fast-changing regulatory environment, and are committed to transparent communication and change notification.

Tags

[excipients](#) [Capsugel](#)

June 29, 2016 3:00 PM

Related



South Carolina Based QC Lab Facility Provides Global Centre of Excellence

Capsugel has doubled its laboratory capacity with the opening of its new Quality Control Laboratory in Greenwood, South Carolina, US..

Nov 30, 2012



Support Service Speeds Up Nutra and Pharma Product Development

Manufacturers of nutraceutical and pharmaceutical products that want to get new products onto the market more quickly and reliably now have access to a new solution: Boost your NutraPharma project, a

service provided by Roquette based on the...

Sep 10, 2013



Supply Chain Programme Now Offers Non-cGMP Ingredients Traceability

Avantor Performance Materials has enhanced its Management of Change (MOC) supply chain alert programme with a new classification to meet the needs of customers wanting full traceability on ingredients not produced under cGMP standards.

Sep 18, 2013



Advancement in liquid dosage excipients (parenteral & transdermal)

This study covers in detail the parenteral and transdermal excipients used in the pharmaceutical industry.

Jul 23, 2014

Comments

 FREE WEBINAR	How to achieve supply chain traceability in the Accomplishing full traceability to safeguard compliance across the enterprise and throughout life science supply chains Thursday 21st July 2016, 14:00 BST
------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Home](#) [News](#) [Technology](#) [Opinion](#) [Directory](#) [Subscribe](#) [Webinars](#)

[About Us](#) [Advertise](#) [Contact Us](#) [Privacy Policy](#) [Terms & Conditions](#)

© 2016 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Built with [Metro Publisher™](#)